BeOne Medicines AG
6160.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$278.99B
Close$
Share Statistics
| Market cap | $278.99 Billion |
|---|---|
| Enterprise Value | $275.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.2 |
| Beta | 0.5 |
| Outstanding Shares | 1,450,485,552 |
Return
| Return on Equity | 12.66% |
|---|---|
| Return on Assets | 7.14% |
| Return on Invested Capital | 13.45% |
Valuation & Multiples
| P/E Ratio | 58.71 |
|---|---|
| PEG | 38.81 |
| Price to Sales | 52.35 |
| Price to Book Ratio | 69.8 |
| Enterprise Value to Revenue | 44.95 |
| Enterprise Value to EBIT | 289.95 |
| Enterprise Value to Net Income | 420 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$1.00
Average shareholder expectationRevenue Estimate
$12.76 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$1.14
Average shareholder expectationRevenue Estimate
$13.77 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BeOne Medicines AG
12,000 employees
CEO: John V. Oyler BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematol...